Olanzapine Neuraxpharm (Olanzapine)

Olanzapine works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors, which reduces excessive dopaminergic and serotonergic activity linked to psychosis and mood instability. Its additional activity at histamine, muscarinic and adrenergic receptors contributes to its overall therapeutic profile.

The appropriate dose of Olanzapine Neuraxpharm is determined by the prescribing clinician based on the individual’s diagnosis, severity of symptoms, age, renal and hepatic function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for olanzapine in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case and discuss alternatives when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olanzapine is known for strong efficacy in controlling psychotic and manic symptoms, often with a higher propensity for metabolic side effects such as weight gain and glucose elevation compared with some other atypicals. Clinicians balance efficacy against tolerability when selecting the most suitable agent for each patient.

Olanzapine Neuraxpharm should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Olanzapine Neuraxpharm is taken orally, usually as a tablet or film‑coated tablet, with or without food. The exact administration schedule—once daily or divided doses—depends on the prescriber’s recommendation and the patient’s clinical response.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe hyperglycemia, and tardive dyskinesia. Patients should be monitored regularly for signs of these conditions, and any sudden changes in health should be reported to a healthcare professional immediately.

Olanzapine is contraindicated in patients with known hypersensitivity to olanzapine or any of its excipients. It should be avoided in individuals with severe central nervous system depression, uncontrolled narrow‑angle glaucoma, or in elderly patients with dementia‑related psychosis due to an increased risk of mortality.